Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Oncology Portfolio Total [legacy] by Quarter
Oncology Portfolio Total [legacy] — Worldwide reported YoY (%) (%)
Pfizer Oncology Portfolio Total [legacy]: 9.0% in Q4 2025, down 18.0 pts from a year earlier.
Latest, Q4 2025
9.0%
Period ended Dec 31, 2025
Change on a year earlier
-18.0 pts
27.0% in Q4 2024
History
32 quarters
Since Q4 2017
Sources
32
Documents cited below
Where the Q4 2025 figure comes from
“|| Oncology | $ | 4,435 | $ | 4,064 | 9% | 8% | $ | 3,327 | $ | 3,051 | 9% | $ | 1,108 | $ | 1,012 | 9% | 7%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Pfizer Oncology Portfolio Total [legacy] (%), quarterly Q4 2017–Q4 2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/port-leg-onc-yoy
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.